ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $1.36B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-656.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $1.34B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-514.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $1.33B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-44.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $12.00K; Additional Paid in CapitalUSD $1.31B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-62.00K.
ARCUTIS BIOTHERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.00K | $1.36B | $-656.00K | $-1.13B | $220.58M | 3 month · $13.07M |
| 2026-03-31 | (m) | $12.00K | $1.34B | $-514.00K | $-1.15B | $189.65M | 3 month · $10.87M |
| 2025-12-31 | (m) | $12.00K | $1.33B | $-44.00K | $-1.14B | $189.48M | 12 month · $41.14M |
| 2025-09-30 | $0.00 | $12.00K | $1.31B | $-62.00K | $-1.16B | $158.07M | 3 month · $10.24M |
| 2025-06-30 | $0.00 | $12.00K | $1.30B | $-35.00K | $-1.16B | $138.97M | 3 month · $10.72M |
| 2025-03-31 | $0.00 | $12.00K | $1.29B | $-140.00K | $-1.15B | $142.66M | 3 month · $9.91M |
| 2024-12-31 | $0.00 | $12.00K | $1.28B | $-7.00K | $-1.12B | $157.54M | 12 month · $42.72M |
| 2024-09-30 | $0.00 | $12.00K | $1.27B | $533.00K | $-1.11B | $156.64M | 3 month · $10.53M |
| 2024-06-30 | $0.00 | $12.00K | $1.26B | $-294.00K | $-1.07B | $186.43M | 3 month · $12.52M |
| 2024-03-31 | $0.00 | $12.00K | $1.24B | $-133.00K | $-1.02B | $224.94M | 3 month · $10.03M |
| 2023-12-31 | $0.00 | $9.00K | $1.07B | $4.00K | $-981.90M | $88.67M | 12 month · $38.81M |
| 2023-09-30 | $0.00 | $6.00K | $962.51M | $-184.00K | $-915.62M | $46.72M | 3 month · $10.00M |
| 2023-06-30 | $0.00 | $6.00K | $951.65M | $-292.00K | $-870.86M | $80.51M | 3 month · $10.58M |
| 2023-03-31 | $0.00 | $6.00K | $940.00M | $-414.00K | $-799.86M | $139.73M | 3 month · $9.48M |
| 2022-12-31 | $0.00 | $6.00K | $930.42M | $-1.09M | $-719.76M | $209.58M | 12 month · $32.68M |
| 2022-09-30 | $0.00 | $6.00K | $920.11M | $-1.60M | $-647.75M | $270.77M | 3 month · $8.79M |
| 2022-06-30 | $0.00 | $5.00K | $736.66M | $-1.25M | $-540.04M | $195.38M | 3 month · $8.10M |
| 2022-03-31 | $0.00 | $5.00K | $727.42M | $-1.02M | $-472.63M | $253.77M | 3 month · $6.53M |
| 2021-12-31 | $0.00 | $5.00K | $706.23M | $-255.00K | $-408.31M | $297.68M | 12 month · $23.89M |
| 2021-09-30 | $0.00 | $5.00K | $699.99M | $-18.00K | $-336.98M | $363.00M | 3 month · $5.36M |
| 2021-06-30 | $0.00 | $5.00K | $694.52M | $-36.00K | $-280.00M | $414.49M | 3 month · $4.34M |
| 2021-03-31 | $0.00 | $5.00K | $688.94M | $42.00K | $-237.99M | $450.99M | 3 month · $8.50M |
| 2020-12-31 | $0.00 | $4.00K | $472.57M | $-2.00K | $-201.95M | $270.62M | 12 month · $7.94M |
| 2020-09-30 | $0.00 | $4.00K | $340.96M | $4.00K | $-167.90M | $173.07M | 3 month · $2.26M |
| 2020-06-30 | $0.00 | $3.00K | $338.62M | $0.00 | $-129.70M | $208.92M | 3 month · $2.05M |
| 2020-03-31 | $0.00 | $3.00K | $336.14M | $19.00K | $-94.28M | $241.88M | 3 month · $990.00K |
| 2019-12-31 | $0.00 | $0.00 | $1.24M | $-1.00K | $-66.27M | $-65.03M | 12 month · $824.00K |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-52.95M | 3 month · $154.00K |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-38.66M | 3 month · $139.00K |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-30.54M | 3 month · $76.00K |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-23.99M | 12 month · $151.00K |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-4.99M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |